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Mortality of Inherited Arrhythmia Syndromes
Insight Into Their Natural History
Eline A. Nannenberg, MD; Eric J.G. Sijbrands, MD, PhD; Lea M. Dijksman, MSc;
Marielle Alders, PhD; J. Peter van Tintelen, MD, PhD; Martijn Birnie, MSc;
Irene M. van Langen, MD, PhD; Arthur A.M. Wilde, MD, PhD
Background—For most arrhythmia syndromes, the risk of sudden cardiac death for asymptomatic mutation carriers is ill
defined. Data on the natural history of these diseases, therefore, are essential. The family tree mortality ratio method
offers the unique possibility to study the natural history at a time when the disease was not known and patients received
no treatment.
Methods and Results—In 6 inherited arrhythmia syndromes caused by specific mutations, we analyzed all-cause mortality
with the family tree mortality ratio method (main outcome measure, standardized mortality ratio [SMR]). In long-QT
syndrome (LQTS) type 1, severely increased mortality risk during all years of childhood was observed (1–19 years), in
particular during the first 10 years of life (SMR, 2.9; 95% CI, 1.5–5.1). In LQTS type 2, we observed increasing SMRs
starting from age 15 years, which just reached significance between age 30 and 39 (SMR, 4.0; 95% CI, 1.1–10.0). In
LQTS type 3, the SMR was increased between age 15 and 19 years (SMR, 5.8; 95% CI, 1.2–16.9). In the SCN5A
overlap syndrome, excess mortality was observed between age 10 and 59 years, with a peak between 20 and 39 years
(SMR, 3.8; 95% CI, 2.5–5.7). In catecholaminergic polymorphic ventricular tachycardia, excess mortality was restricted
to ages 20 to 39 years (SMR, 3.0; 95% CI, 1.3–6.0). In Brugada syndrome, excess mortality was observed between age
40 and 59 (SMR, 1.79; 95% CI, 1.2–2.4), particularly in men.
Conclusions—We identified age ranges during which the mortality risk manifests in an unselected and untreated
population, which can guide screening in these families. (Circ Cardiovasc Genet. 2012;5:183-189.)
Key Words: arrhythmia  long-QT syndrome  Brugada syndrome  catecholaminergic polymorphic ventricular tachycardia
 mortality  pedigree  natural history
The molecular genetic substrate of various inherited ar-rhythmia syndromes has been identified in recent years.1
As a result, an increasing number of mutations in mostly
symptomatic probands has been identified. This has facili-
tated genotyping of family members and identification of
mutation carriers before they develop symptoms. In symp-
tomatic, untreated patients, the risk of sudden cardiac death
(SCD) is substantial; however, in asymptomatic mutation
carriers, the risk is ill defined. Preventive lifestyle advice may
be given and pharmacological and invasive treatment offered.
However, such therapies may have side effects and a signif-
icant impact on quality of life.2,3 A number of pressing
questions remain unanswered. Should all asymptomatic car-
riers of a disease-causing mutation be treated? If so, at which
age should treatment be started, and from what age onward
can treatment be safely withheld in asymptomatic patients?
What are the optimal genetic and cardiological screening
strategies?
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To address these issues, data on the natural history of the
disease are required, but they are scarce because published
studies have a strong bias toward symptomatic patients.4
Therefore, we investigated the mortality with the family tree
mortality ratio (FTMR) method5–7 in 6 major autosomal-
dominant inherited arrhythmia syndromes caused by specific
mutations, including long-QT syndrome types 1, 2, and 3
(LQTS1, LQTS2, LQTS3), Brugada syndrome, SCN5A over-
lap syndrome (LQTS3/Brugada syndrome/conduction dis-
ease),8 and RYR2-related catecholaminergic polymorphic
ventricular tachycardia (CPVT). This method allowed us to
study mortality in times when the disease was not known and
Received May 31, 2011; accepted December 29, 2011.
From the Department of Clinical Genetics (E.A.N., M.A.) and Heart Failure Research Center (E.A.N., L.M.D., M.B., A.A.M.W.), Department of
Cardiology, Academic Medical Center, Amsterdam, The Netherlands; Department of Internal Medicine, Division of Pharmacology, Vascular and
Metabolic Diseases, Erasmus Medical Center, Rotterdam, The Netherlands (E.J.G.S.); and Department of Clinical Genetics, University Medical Center
Groningen, University of Groningen, Groningen, The Netherlands (J.P.T., I.M.L.).
The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.111.961102/-/DC1.
Correspondence to Eline A. Nannenberg, MD, Department of Clinical Genetics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The
Netherlands. E-mail e.a.nannenberg@amc.uva.nl
© 2012 American Heart Association, Inc.
Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org DOI: 10.1161/CIRCGENETICS.111.961102
183
therapy was not available and, thus, provided information on
the natural course of the disease.
LQTS is characterized by a prolongation of the QT interval
on the ECG and is associated with torsades de pointes
ventricular tachycardia and ventricular fibrillation. The esti-
mated prevalence of LQTS is 1:2000.9 The 3 most prevalent
(sub-)types are LQTS1, LQTS2, and LQTS3, which are
caused by mutations in the KCNQ1, KCNH2, and SCN5A
genes, respectively. Although cardiac events may occur from
infancy through middle age, they are most common from the
preteen years through the 20s. Patients with LQTS1 exhibit a
high rate of cardiac events during childhood and adolescence,
but the incidence of death is similar in all 3 types at 4%
before age 40 in patients and their relatives.4,10–12 CPVT
is associated with adrenergically induced ventricular
tachyarrhythmias. The first studies on CPVT reported high
mortality rates in children. More recent studies, however,
showed a later onset of SCD, where 30% to 50% of SCD
occurs at age 30 to 40 years when untreated.13–18 In Brugada
syndrome, malignant events can occur at all ages, with a peak
around the fourth decade of life. There is a striking male-to-
female ratio of 8:1.19,20 In the present study, we assessed the
mortality of these inherited arrhythmia syndromes by study-
ing mutation carriers at a time when the disease was not yet
known and untreated.
Methods
Identification of Mutation Carriers and
Reconstruction of Family Trees
We reconstructed large family trees of patients seen in the genetic
testing program of inherited arrhythmia syndromes at our cardioge-
netics department. For 5 inherited arrhythmia syndromes (LQTS1,
LQTS2, LQTS3, CPVT, and SCN5A overlap syndrome), the first
step was to search for sets of at least 2 clinically affected probands
who carried the same mutation. Sets of probands with an (almost)
identical haplotype (and a large likelihood of having a distant
common ancestor) were selected for further genealogical analysis.
Genealogical analysis was conducted until a shared distant pair of
ancestors was identified. Subsequently, family trees were recon-
structed by tracing the descendants of these pairs of ancestors and
including all siblings in each generation. Thus, these family trees
contained certain (genotyped or obligate) mutation carriers and those
with a 50% chance of being a carrier (siblings of certain carriers).
Furthermore, in some family trees, the additional transmission lines
of the specific mutation through the family trees were identified by
testing living descendents. In this way, we reconstructed large family
trees of families with the following mutations: c.565GA
(p.Gly189Arg) in KCNQ1 (LQTS1); c.296AC (p.Tyr99Ser) in
KCNH2 (LQTS2); c.5302AG (p.Ile1768Val) in SCN5A (LQTS3);
c.5385_5387dup (p.1795insAsp), a Dutch founder mutation in
SCN5A (SCN5A overlap syndrome; LQTS3/Brugada syndrome/
conduction disease)8; and c.1258CT (p.Arg420Trp) in RYR2
(CPVT). For Brugada syndrome, we further collected 37 small
contemporary family trees (the proband with all first-degree rela-
tives) with a mutation in SCN5A (online-only Data Supplement
Table). Some family trees were extended by testing the specific
mutation through the pedigree.
Subsequently, from all individuals in the family trees, data on birth
and death were obtained from official Dutch archives. In The
Netherlands, these data are very well preserved from the beginning
of the 19th century (1811) and have been collected of all inhabitants.
We excluded all probands because they had to be alive to visit our
cardiogenetics clinic and would therefore introduce bias to years
without deaths. The years of life of the parents before birth of the
(obligate) mutation carriers were excluded to avoid reproduction bias
because they must have been living until this age to transmit the
mutation to their offspring. We excluded the first year of life of all
individuals from all the analyses because registration of neonatal
mortality in the 19th century might not have been accurate. We
ended all analyses at death, when a diagnosis was made in an
individual (and treatment was started), or in the year when the
mutation was identified (and when presymptomatic testing became
available and treatment could have been started). All probands gave
informed consent to the study.
Statistics (FTMR Method)
The mortality in the family trees (observed mortality) was compared
to the mortality of the general Dutch population (expected mortality)
standardized for age, sex, and calendar period, as previously de-
scribed.5–7,21,22 The ratio of observed-to-expected mortality is the
standardized mortality ratio (SMR). The expected mortality was
calculated by multiplying the total number of years lived by the study
population in each calendar period per sex and age category with the
age- and sex-specific mortality rates of the Dutch population for each
calendar period, which were available at Statistics Netherlands using
the computer program Person-Years.23 The 95% CI of the SMR was
calculated assuming a Poisson distribution of the observed number of
deaths and by using exact limits.
We analyzed the following arbitrary age categories: from 1 to 19,
20 to 39, 40 to 59, 60 to 79, and 80 to 109 years. These 20-year
categories were chosen to avoid relatively empty cells and to enable
comparison with similar data in the literature. In addition, we showed
relevant smaller age categories in an inset when (significantly)
increased mortality was observed in these specific age categories.
Results
Family Trees
Five large family trees were reconstructed, dating back to the
18th and 19th centuries (Figure 1, online-only Data Supple-
ment Figure). Furthermore, 37 small family trees (Brugada
syndrome) were reconstructed, comprising 508 (246 male,
262 female) relatives. The Table gives an overview of the
characteristics of the family trees.
Mortality Risk
Long-QT Syndrome Type 1
Between 1811 and 2001 (when the mutation was detected in
the family), 45 deaths (between age 1 and 109 years) occurred
in 2533 person-years among 59 persons. The overall SMR
was 1.5 (95% CI, 1.1–2.0). In particular, we observed
significant and severe excess mortality from age 1 to 19 years
(SMR, 3.0; 95% CI, 1.7–5.0) (Figure 2A). Additional analy-
ses identified a smaller specific age category in which the
excess mortality was significant (Figure 2A, inset). Between
age 1 and 9 years, the SMR was 2.9 (95% CI, 1.5–5.1), and
between 10 and 19 years, the SMR was high (3.4; 95% CI,
0.7–9.9) but not statistically significant.
Long-QT Syndrome Type 2
Between 1852 and 2003, 25 deaths occurred in 3728 person-
years among 78 persons. The mean SMR over that period was
0.9 (95% CI, 0.6–1.3); that is, there was no overall excess
mortality. Between age 1 and 14 years, there were no
observed deaths. From age 15 years, the SMR started to
increase (15–19 years SMR, 2.6; 95% CI, 0.1–14.7). Only
between age 30 and 39 years did excess mortality reach
significance (SMR, 4.0; 95% CI, 1.1–10.0) (Figure 2B).
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Long-QT Syndrome Type 3
Between 1811 and 2004, 32 deaths occurred in 2216 person-
years among 44 persons. The mean SMR was 1.0 (95% CI,
0.7–1.4). When looking at smaller age categories, there was
severe excess mortality between age 15 and 19 years (SMR,
5.8; 95% CI, 1.2–16.9) (Figure 2C, inset).
SCN5A Overlap Syndrome
Between 1811 and 1998, 92 deaths occurred in 10 510
person-years among 308 persons. The SMR was 1.5 (95% CI,
1.2–1.8). A closer look revealed that severe excess mortality
started after age 10 years (10–14 years SMR, 9.8; 95% CI,
4.2–19.2) and peaked between 20 and 39 years (SMR, 3.8;
95% CI, 2.5–5.7). Over age 60, no excess mortality was
observed (Figure 2D).
Catecholaminergic Polymorphic Ventricular Tachycardia
Between 1858 and 2004, 36 deaths occurred in 6362 person-
years among 173 persons. The overall SMR was 1.1 (95% CI,
0.8–1.5). In the age category of 20 to 39 years, significant
excess mortality was observed (SMR, 3.0; 95% CI, 1.3–6.0).
When looking at smaller age categories (Figure 2E, inset)
between 20 and 29 years, the SMR was more severely
Figure 1. Family tree with long-QT syndrome type 1. The probands are indicated with an arrow. Solid squares indicate 100% (obligate)
male carriers; open circles, female family members with a 50% probability of carriership; semisolid square or circle, male or female
family member with a 50% probability of carriership (ancestor pair). The numbers in the open circles or squares indicate the total num-
ber of siblings. Crossed off family members have passed away.




















LQTS1 (KCNQ1) c.565GA (p.Gly189Arg) 1760 59 11 48 27 32 45 2533 1.5 (1.1–2.0)
LQTS2 (KCNH2) c.296AC (p.Tyr99Ser) 1852 78 16 62 34 44 25 3728 0.9 (0.6–1.3)
LQTS3 (SCN5A) c.5302 AG (p.Ile1768Val) 1758 44 9 35 23 21 32 2216 1.0 (0.7–1.4)
SCN5a overlap
syndrome (SCN5A)
c.5385_5387dup (p.1795insAsp) 1803 308 32 276 160 148 92 10 510 1.5 (1.2–1.8)





1877 508 121 387 262 246 102 22 150 0.8 (0.7–1.0)
SMR indicates standardized mortality ratio; LQTS1, LQTS2, LQTS3, long-QT syndrome types 1, 2, and 3; CPVT, catecholaminergic polymorphic ventricular
tachycardia.
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increased (3.7; 95% CI, 1.2–8.6). Over age 40, no excess
mortality was observed (Figure 2E).
Brugada Syndrome
Between 1877 and 2009, 102 deaths occurred in 22 150
person-years among 508 persons. The SMR was 0.8 (95% CI,
0.7–1.0). From age 40 to 59 years, we observed significant
excess mortality (SMR, 1.72; 95% CI, 1.2–2.4). When
looking at smaller categories, between age 40 and 49 years,
an SMR of 2 just reached significance (95% CI, 1.05–3.4).
When looking at sex, in men aged 40 to 59 years, the SMR
was 2.0 (95% CI, 1.2–3.0); in females, no excess mortality
was observed in any age category (Figure 2F).
Discussion
For most arrhythmia syndromes, it is not well-known to what
extent asymptomatic carriers are at risk for SCD. At the same
time, physicians face an increasing need for data about the
natural history when decisions about preventive measures and
screening strategies have to be made for a rapidly increasing
number of asymptomatic gene carriers. The FTMR method
Figure 2. All-cause mortality (SMR) with 95% CIs by age category and male and female sex. A, Long-QT syndrome (LQTS) type 1. In
the inset, smaller age categories are depicted. B, LQTS type 2. C, LQTS type 3. D, SCN5A overlap syndrome. E, Catecholaminergic
polymorphic ventricular tachycardia. F, Brugada syndrome in male subjects (i) and female subjects (ii). SMR indicates standardized
mortality ratio.
186 Circ Cardiovasc Genet April 2012
offers the unique possibility to study the mortality of inher-
ited arrhythmia syndromes at a time when the disease was not
known and patients received no treatment. Unfortunately, the
design of the present mortality study does not allow extrap-
olation to the morbidity from these disorders.
We realize that we studied specific mutations in a number
of families and that the results cannot be generalized to all
families with these inherited arrhythmias. Yet, in syndromes
where classes of mutations share pathophysiological mecha-
nisms, FTMR data on one of them may be relevant to the
larger group. In line with this, it has been shown that
biophysical function, location, and type of KCNQ1 mutations
are important independent risk factors influencing the clinical
course of a disorder,24,25 and comparable data as to location
and type of KCNH2 mutations have been presented.26 Ideally,
more large families should be studied with the FTMR method
to obtain evidence if the present results can be generalized,
and consortia should be formed to cluster the data of
pedigrees with identical mutations to study the effect of
genetic modifiers on the burden of these disorders.
When interpreting the present results, one must take into
account that as a result of analyzing complete sibships
(certain carriers and all siblings) in each generation, the
estimates express at least 50% of the excess risk, implying
that the excess mortality in certain carriers is even higher
than the increased SMRs that we found. However, if the
reported observed SMRs are (around) 1, the SMR of
certain carriers can only also be 1 because the SMR of the
general population is 1.
We excluded the first year of life of all individuals from all
the analyses because registration of neonatal mortality in the
19th century might not have been accurate. As a conse-
quence, we could not analyze sudden infant death syndrome.
We observed clear excess mortality in the families relative to
the Dutch population, especially in young age categories in
some arrhythmia syndromes. For this reason and because the
analyses were based on age-specific rates, the analyses are
unlikely to have been affected by a competing risk (ie,
mortality from other causes in the past, mainly infectious
diseases, was so high that people died of other causes before
they could die of the arrhythmia syndromes).27
We identified specific age categories in patients with
LQTS1, LQTS2, LQTS3, SCN5A overlap syndrome, CPVT,
and Brugada syndrome to which the excess mortality was
limited. These age categories compare well from what is
known from data on predominantly symptomatic probands. In
LQTS1 [caused by the c.565GA (p.Gly189Arg) mutation],
severe increased mortality during childhood was observed
(age 1–19 years), particularly during the first 10 years of life
(Figure 2A). In LQTS2 [caused by the c.296AC
(p.Tyr99Ser) mutation], we observed increasing SMRs start-
ing from age 15 years, which just reached significance
between 30 and 39 years. In LQTS3 [caused by the
c.5302AG (p.Ile1768Val) mutation], SMR was increased
between 15 and 19 years. Taking into account the consider-
ations discussed previously, these data (the first in our
knowledge to be based on data in times when the disease was
not known and therapy was not available) show that these
patients with LQTS1 are mainly at risk before age 20 years
(more particularly, age 10 years) and in patients with LQTS2
and LQTS3, from puberty onward. In contrast to children and
adolescents, adults aged 40 years in the present LQTS1,
LQTS2, and LQTS3 families had no excess mortality. Per-
sons with SCN5A overlap syndrome demonstrated significant
and severe excess mortality between age 10 and 59 years,
with a peak between 20 and 39 years. In CPVT [caused by the
c.1258CT (p.Arg420Trp) mutation in RYR2], excess mor-
tality was restricted to age 20 to 39 years (particularly, age
20–29 years). In Brugada syndrome (caused by multiple
mutations), excess mortality was restricted to age 40 to 59
years, particularly in men.
There is little doubt that the International LQTS Registry
of probands and present-day relatives has been instrumental
in the current knowledge of the risk of patients with LQTS.
Genotype-specific risk for symptoms, including aborted car-
diac arrest and SCD, have been published for different age
categories.10,12,28,29 Comparable with the present FTMR data,
patients with LQTS1 have been reported to have the highest
risk of cardiac events during childhood and adolescence,
whereas patients with LQTS2 maintain a high event rate
throughout adulthood.10 When limited to death (the parameter
studied by the FTMR method) or cardiac arrest, patients with
LQTS1 are also more severely affected before puberty,
whereas casualties in the LQTS2 and LQTS3 population are
more prevalent during or after puberty.12 However, in a
larger, more recent series of patients, when limited to life-
threatening events (aborted cardiac arrest and SCD), differ-
ences among the 3 LQTS genotypes were attenuated before
age 40.10 Published data suggest a slightly increased risk of
life-threatening events for age 18 years, particularly age
40 years, in all genotypes, with probably a greater risk in
patients with LQTS2 and LQTS3.10,28,30 The present data do
not show an increased mortality risk for age 40 years (in
patients who were untreated before that age). This can be the
result of the unselected population: Patients were selected by
Mendelian inheritance and not because they had a severe
clinical phenotype. Alternatively, it might reflect the specific
clinical course of the mutations we studied, as most literature
is based on pooled patients with different mutations.
In previous studies on the clinical presentation of CPVT,
the mean age of clinical presentation was 8 years. If left
untreated, 80% of patients with CPVT develop symptoms
(syncope, ventricular tachycardia, or ventricular fibrillation)
by age 40.13–18,31 The median age of lethal events was 188
years in a study by Priori et al16 and 28 years in a study by
Postma et al,18 and in a recent study by Hayashi et al,17 a fatal
or near-fatal event occurred between age 13 and 26 years. The
excess mortality between age 20 and 39 years in the present
study is on the late end of the age ranges described but can
reflect the specific clinical course of the mutation in this
family. In Brugada syndrome, the data are in line with the
existing literature, reporting a peak in malignant events in the
fourth decade of life, with men predominantly affected.20,32,33
These data might help to guide treatment and genetic and
cardiological screening strategies in families with an inher-
ited arrhythmia syndrome. Our best example, because of its
large size, is the family with the SCN5A overlap syndrome.
Based on the increased overall SMR and the mortality per age
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category, cardiological and genetic screening of the first-
degree family members of SCN5A overlap syndrome muta-
tion carriers is justified from age 5 until age 60 years (the
SMR starts to increase between age 5 and 9 years and is
significantly increased from age 10 until age 60). Further-
more, implantation of a pacemaker or implantable
cardioverter-defibrillator (which is at the moment the stan-
dard procedure in mutation carriers)34 may be postponed until
well after age 5 and is not needed after age 60 in asymptom-
atic patients not treated before. In the LQTS families, the high
mortality risks at a young age justifies (active) cardiological
and genetic screening of the first-degree family members of
LQTS probands with the described mutations at a very young
age, particularly in LQTS1. For the CPVT family, the
mortality risk for ages 20 and 40 years was not statisti-
cally different from the Dutch population. Untreated asymp-
tomatic carriers in this family, who were identified with
family screening, may therefore lack an indication for treat-
ment (-blockers) at ages 40 years; hence, the present data
do not support the advice to always start -blocker treatment
in carriers of the c.1258CT mutation, even when there is no
history of cardiac events and no arrhythmias on stress
testing.35,36 We emphasize that our advice does not account
for other families where CPVT is caused by a different RYR2
mutation. In Brugada syndrome, the data are pertinent to 1
mutation and accurately follow the known clinical presenta-
tion; hence, insight into the mortality of the disease warrants
an expectative policy (with proper lifestyle adjustments [ie,
fighting fever]), particularly in asymptomatic female mem-
bers in the first 3 decades of life.
In conclusion, using the unique FTMR method, we studied
all-cause mortality and quantified the risk for death in the
main inherited arrhythmia syndromes by collecting data from
a time when these diseases were unknown and patients were
not treated for the disease. As such, we were able to describe
the natural history of these diseases caused by specific
mutations. We identified age ranges during which the risk for
lethal events is increased in untreated patients. The data might
help to further guide screening and treatment strategies in an
increasing group of asymptomatic mutation carriers detected
through molecular genetic testing in families with an inher-
ited arrhythmia syndrome.
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CLINICAL PERSPECTIVE
For most arrhythmia syndromes, the risk of sudden cardiac death for asymptomatic mutation carriers is ill defined. Data
on the natural history of these diseases are, therefore, essential for clinicians. The family tree mortality ratio method offers
a unique opportunity to study the natural history at a time when the disease was not known and patients received no
treatment (in large pedigrees tracing back many generations). In 6 inherited arrhythmia syndromes (3 long-QT syndrome
subtypes, SCN5A overlap syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome)
caused by specific mutations, we analyzed all-cause mortality with the family tree mortality ratio method, with the main
outcome measure being the standardized mortality ratio. In all arrhythmia syndromes, excess mortality was observed in
specific age categories. For these families, this information can be directly translated into clinical practice through guiding
genetic and cardiovascular treatment and screening. For example, for the long-QT syndromes, excess mortality was
observed in young age categories, particularly in type 1. We therefore advise starting genetic screening and cardiovascular
screening of the first-degree family members at a very young age. In an SCN5A overlap syndrome family, excess mortality
is from age 10 to 60 years (but starts to increase from age 5 years); therefore, implantation of a pacemaker may be
postponed until well after age 5. For Brugada syndrome families, excess mortality was observed between age 40 and 59
years, especially in men. This finding warrants an expectant policy, particularly in asymptomatic female members in the
first 3 decades of life.
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